Daily price updates
What planify offer?
Join our channel partner program
₹390.00
Available in Depository:
NSDL
CDSL
Available for Investment:
Primary
Secondary
RECOMMENDATION
Strong Buy
Business Type
Dominant Leader
RATING
RECOMMENDATION
Strong Buy
Business Type
Dominant Leader
EBITDA
The EBITDA of the company has witnessed a marginal growth of 5% in FY21 from FY20, which represents an aggregate increase of Rs. 4 Cr. The overall increase in the EBITDA is attributable to an increase in the revenue of the company
Total Revenue
The total revenue of the company in FY21 has witnessed a steady growth of 5% from FY20. An increase in the revenue from operations is attributable to TPA fees, which had risen on account of the COVID-19 pandemic and an increase in health insurance premiums in India, which witnessed 13.3% growth in GDPI in FY21.
241.58
241.58
86.06
67.4
63.86
43.88
6.57
6.51
-
-
281.17
281.17
86.84
63.68
48.07
32.97
4.93
4.9
-
-
330.44
330.44
89.51
63.18
59.45
38.15
5.71
5.66
-
-
348.2
348.2
97.89
66.37
60.64
37.71
5.63
5.57
-
-
EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ Cr
* denotes current year's data